(OSI) Oncology is focused on developing molecular targeted
therapies designed to change the paradigm of cancer care. Ventavis(R) is
marketed in the United States by CoTherix for the treatment of pulmonary
arterial hypertension, a highly debilitating and potentially fatal disease
characterized by high blood pressure in the pulmonary arteries of the lungs ,
in patients with NYHA Class III or IV symptoms.m. Food
and Drug Administration (FDA) on December 29, 2004 for the treatment of PAH
(WHO Group I) in patients with NYHA Class III or IV symptoms.4Ventavis .

pemphigoid tachycardia

3-mg dose once every six weeks by intravitreal injection.
Increases in intraocular pressure (IOP) have been seen within 30 minutes
of injection with Macugen.S. OSI commercializes Macugen in partnership with Pfizer Inc.

In clinical studies of Ventavis as monotherapy, common adverse reactions
due to Ventavis included: vasodilation (flushing, 27%), cough (39%), headache
(30% ), flu syndrome (14%), nausea (13%), trismus (12%), hypotension (11%),
insomnia (8%) and syncope (8%); other serious adverse events reported with the
use of Ventavis included congestive heart failure , chest pain,
superventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Ventavis is an
inhaled formulation of iloprost, a synthetic compound that is structurally
similar to prostacyclins .

Forward-Looking Statements
The statements contained in this press release that are not purely
historical are forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended.

pterygium priapism

Proper aseptic injection technique -- which includes
use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or
equivalent ) -- should always be utilized when administering Macugen.
Most frequently reported adverse events in patients treated for up to two
years were anterior chamber inflammation, blurred vision, cataract ,
conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye
pain, hypertension , increased IOP, ocular discomfort, punctate keratitis,
reduced visual acuity, visual disturbance , vitreous floaters, and vitreous
opacities.
The following data on Ventavis will be presented on Sunday, May 22 from
10:45 a. Our actual results
could differ materially from our current expectations .

pemphigoid phenylketonuria

D., chief executive officer
of (OSI) Eyetech and executive vice president of OSI Pharmaceuticals . (OSI) Prosidion is committed to the generation of
novel, targeted therapies for the treatment of type 2 diabetes and obesity.com

); Poster K28

-- "Safety, Dosing, and Clinical Benefit of 2-Year Therapy with Inhaled
Iloprost" (H.cotherix. The results of initial
clinical trials do not necessarily predict the results of later stage clinical
trials.

poliodystrophy pruritis

, PR Pharmaceuticals , Inc."
"For PRP, this agreement demonstrates the value of our broad intellectual
property estate and expertise in the formulation of sustained release large
molecules," said Steve Howe, chief executive officer of PRP.

About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicines and changing lives"
by discovering, developing and commercializing high-quality and novel
pharmaceutical products that extend life or improve the quality of life for
patients with cancer, eye diseases, and diabetes. and with Roche throughout the
rest of the world.

proteinuria periodontitis

com.

Important Safety Information
Macugen is contraindicated in patients with ocular or periocular
infections. PRP's lead products
under development are InsuLAR(TM), a once-a-week basal insulin injection and
PulmoLAR(TM), a sustained release preparation for the treatment of Pulmonary
Arterial Hypertension.
PRP collaborates with other pharmaceutical companies who desire to enhance
the benefits of their proprietary molecules through PRP's sustained release
technologies.

New Ventavis (R) Data to Be Presented at American Thoracic Society's International Conference

Ventavis should not be initiated in
patients with systolic blood pressure lower than 85 mm Hg.

About PAH
PAH affects an estimated 50,000 patients in the United States, with only
about 15,000 diagnosed and under treatment. We
cannot guarantee that any product candidate, including any combination
therapy , will receive FDA or other regulatory approval or that we will seek
any such approval.

pemphigus phenylketonuria

Therefore , IOP as well as the perfusion of the
optic nerve head should be monitored and managed appropriately . For
additional information about OSI, please visit http://www.com.S.
For important additional information concerning the safety and use of
Ventavis, please see the prescribing information available at
http://www.

pseudomembranous pemphigus

Prior to the
introduction of Ventavis, prostacyclin therapies for PAH required continuous
delivery through subcutaneous or intravenous routes -- invasive treatments
which can be difficult to tolerate and/or require complicated maintenance.
Because of the risk of syncope, vital signs should be monitored while
initiating Ventavis.

rombergs periodontitis

"We are proud to
partner with OSI . OSI will reimburse
PRP for efforts carried out by PRP in support of the collaboration. In
addition , patients should be monitored during the week following the injection
to permit early treatment, should an infection occur. These events occurred in approximately 10% to 40% of patients.

pemphigus pruritis

in the U .m.
Now, with Ventavis, PAH patients can benefit from a non-invasive, inhaled
treatment option .

platelet acidemia

The company has unique sustained release injectable technologies and uses
these primarily to develop its own proprietary products. Its cause may be unknown, or
result from other diseases that cause a restriction of blood flow to the
lungs, including scleroderma, HIV and lupus.

pruritis hallervorden

"
PRP received an undisclosed upfront payment from (OSI) Eyetech and also
will receive payments for achieving certain milestones and royalties on net
sales of any products resulting from the collaboration. For more information visit booth #740.

periodontitis hallervorden

Collaboration Aims to Improve Dosing Convenience for Patients Treated for
Neovascular Age-Related Macular Degeneration (neovascular AMD)

FORT COLLINS, Colo. Dose adjustments or a change in therapy should be
considered if exertional syncope occurs.

poliomyelitis vegetative

About Macugen
Macugen is indicated in the United States for the treatment of neovascular
age-related macular degeneration (neovascular AMD) and is administered in a
0.
Serious adverse events related to the injection procedure occurring in <1%
of intravitreal injections included endophthalmitis, retinal detachment, and
iatrogenic traumatic cataract.osip. Stop Ventavis
immediately if signs of pulmonary edema occur, this may be a sign of pulmonary
venous hypertension .

About Cotherix, Inc. CoTherix's Ventavis (iloprost)
Inhalation Solution was approved by the FDA in December 2004 for the treatment
of pulmonary arterial hypertension, a highly debilitating and potentially
fatal disease characterized by high blood pressure in the pulmonary arteries
of the lungs, in patients with NYHA Class III or IV symptoms. Factors that could
cause or contribute to such differences include, but are not limited to,
factors described from time to time in our filings with the Securities and
Exchange Commission, including those discussed in the "Risk Factors and Other
Uncertainties" section of our Annual Report on Form 10-K filed on March 31,
2005.

poliodystrophy platelet

Intravitreal injections including those with Macugen have been associated
with endophthalmitis. Rubin, MD, et al.

tachycardia periodontitis

The agreement gives OSI and its development
and marketing partner Pfizer access to a proprietary method for encapsulating
Macugen for use in ophthalmology.

About PR Pharmaceuticals, Inc . (Nasdaq: CTRX) today announced that data on Ventavis(R) (iloprost)
Inhalation Solution will be presented at the annual International Conference
of the American Thoracic Society (ATS), May 20-25 in San Diego .
CoTherix, Inc. All forward-looking statements included in this press
release are based upon information available to us as of the date hereof, and
we assume no obligation to update any such forward-looking statement as a
result of new information, future events or otherwise.

pallister orthostatic

"This collaboration brings together the scientific and technical expertise
to develop a sustained release formulation of Macugen, our breakthrough
medicine for neovascular AMD," said David Guyer, M. Abstracts include:

-- "Efficacy of Inhaled Iloprost in NYHA Class IV Pulmonary Hypertension
(PH)" (H.com.

pallister vegetative

PR Pharmaceuticals (PRP) Announces Collaboration With OSI Pharmaceuticals to Develop Sustained Release Formulation of Macugen(R) (pegaptanib sodium injection)

announced today an exclusive agreement with OSI Pharmaceuticals to collaborate
on the development of a sustained release formulation of Macugen(R)
(pegaptanib sodium injection), a novel treatment for neovascular age-related
macular degeneration (neovascular AMD), using PRP's proprietary ProPhase(TM)
encapsulation technology . PRP is responsible for developing the
formulations and manufacturing the test article for non-clinical and clinical
trials. OSI, through its eye disease unit (OSI) Eyetech, is responsible for
clinical development activities and has the right to manufacture and
commercialize any resulting product.

VEGF is a protein that plays a critical role in angiogenesis (the
formation of new blood vessels ) and increased permeability (leakage from blood
vessels), two pathological processes that contribute to the vision loss
associated with neovascular AMD. The Company operates
through three business teams, (OSI) Oncology, (OSI) Eyetech and (OSI)
Prosidion. More information about PRP on our website http://www.); Poster K29

-- "Maintenance of Clinical Benefit of Inhaled Iloprost during Trough
Periods" (L. Ventavis is the
newest entry into the prostacyclin class of PAH treatments . More
information can be found at http://www.

pinkeye hallervorden

OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered
and developed by OSI to obtain FDA approval and the only EGFR inhibitor to
have demonstrated the ability to improve survival in both non-small cell lung
cancer and pancreatic cancer patients.prpharm.

pernicious pinkeye

PRP is a Fort Collins, CO based privately held Biopharmaceutical Company . Olschewski, MD, et al.J.

periodontitis rombergs

Under the terms of the collaboration, PRP grants OSI Pharmaceuticals an
exclusive license to use PRP's ProPhase(TM) technology with respect to Macugen
in the treatment of eye diseases. Macugen is a
pegylated anti-VEGF aptamer, which binds to vascular endothelial growth factor
(VEGF).macugen. SOUTH SAN FRANCISCO, Calif. to 12:15 p. Olschewski, MD, et al. CoTherix and the CoTherix logo are trademarks of
CoTherix, Inc. Ventavis is a trademark of Schering AG, Germany .

pruritis hallervorden

Ventavis has not been evaluated in patients with chronic
obstructive pulmonary disease (COPD), severe asthma, or with acute pulmonary
infections. Left
untreated, the median survival time following diagnosis may be as short as
three years.

hallervorden pallister

); Poster K61

Four additional abstracts related to Ventavis will be presented at the
meeting. Symptoms of the disease include
fatigue, shortness of breath on exertion, chest pain and dizziness.

tachycardia pemphigus

"Dosing
convenience is important for retina specialists and patients who are fighting
age-related blindness. (OSI) Eyetech
specializes in the development and commercialization of novel therapeutics to
treat diseases of the eye.

About Ventavis
Ventavis(R) (iloprost) Inhalation Solution was approved by the U.com.

propionic poliomyelitis

For full prescribing information about Macugen, please visit
http://www. OSI markets Tarceva through
partnerships with Genentech, Inc. Macugen(R) (pegaptanib sodium injection) is approved in
the United States for the treatment of neovascular age-related macular
degeneration., CoTherix,
Inc. PT, during the ATS Thematic Poster Session for
Pulmonary Hypertension. is a biopharmaceutical company focused on licensing ,
developing and commercializing therapeutic products for the treatment of
cardiopulmonary and other chronic diseases. Data collected from clinical trials are subject to varying
interpretation , and may be deemed insufficient by the FDA or other regulatory
bodies reviewing applications for market approval or label expansion
(including combination therapy) of any product or product candidate .

vegetative acidemia

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)